{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:01Z","timestamp":1789706041226,"version":"4.0.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T00:00:00Z","timestamp":1320364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0026904","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T20:46:06Z","timestamp":1320439566000},"page":"e26904","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00430924","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lene","family":"Boesby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Elung-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Wirenfeldt","family":"Klausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Strandgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Kamper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,11,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.","volume":"65","author":"D de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1523-1755.2001.0600031131.x","article-title":"Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.","volume":"60","author":"TH Jafar","year":"2001","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.","volume":"123","author":"JC Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN).","volume":"53","author":"P Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.","volume":"63","author":"P Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial.","volume":"5","author":"AL Kamper","year":"1992","journal-title":"Am J Hypertens"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2215\/CJN.01110905","article-title":"Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.","volume":"1","author":"Y Kanno","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","article-title":"Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.","volume":"37","author":"M Epstein","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/snep.2001.26797","article-title":"Aldosterone in progressive renal disease.","volume":"21","author":"TH Hostetter","year":"2001","journal-title":"Semin Nephrol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10157-008-0034-9","article-title":"Aldosterone and glomerular podocyte injury.","volume":"12","author":"M Nagase","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.","volume":"70","author":"S Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.","volume":"1","author":"A Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.","volume":"18","author":"A Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy.","volume":"68","author":"KJ Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.","volume":"70","author":"KJ Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.","volume":"1","author":"M Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.","volume":"41","author":"WB White","year":"2003","journal-title":"Hypertension"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph3010001","article-title":"Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?","volume":"3","author":"P Cravedi","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.","volume":"20","author":"UF Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.","volume":"31","author":"Y Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.","volume":"52","author":"L Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.","volume":"46","author":"S Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/01.RES.0000106135.02935.E1","article-title":"Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone.","volume":"93","author":"TR Uhrenholt","year":"2003","journal-title":"Circ Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.","volume":"47","author":"M Nagase","year":"2006","journal-title":"Hypertension"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.mce.2003.10.047","article-title":"Aldosterone target organ protection by eplerenone.","volume":"217","author":"AE Rudolph","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jsbmb.2006.09.018","article-title":"Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation.","volume":"102","author":"S Arima","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.steroids.2007.12.010","article-title":"Rapid non-genomic effects of aldosterone on the renal vasculature.","volume":"73","author":"BM Schmidt","year":"2008","journal-title":"Steroids"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/en.2004-1130","article-title":"Eplerenone blocks nongenomic effects of aldosterone on the Na+\/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels.","volume":"146","author":"L Michea","year":"2005","journal-title":"Endocrinology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.","volume":"15","author":"B Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).","volume":"118","author":"B Pitt","year":"2008","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.","volume":"351","author":"DN Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone.","volume":"31","author":"A Struthers","year":"2008","journal-title":"Clin Cardiol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0026904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:30:02Z","timestamp":1589041802000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0026904"}},"subtitle":[],"editor":[{"given":"Niels Olsen Saraiva","family":"C\u00e2mara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,11,4]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,11,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0026904","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,4]]}}}